PharmacyCodes



Quibron-T en es it fr

Categoria

Quibron-T Marchi, Quibron-T Analoghi

Quibron-T Marchi miscela

  • Bronchyl Syrup (alcohol anhydrous + beechwood creosote + cocillana + eucalyptus + guaiacol oleate + ipecac + lobelia inflata + menthol + myroxylon balsamum + theophylline + white pine)
  • Choledyl Expectorant Elixir (guaifenesin + oxtriphylline)
  • Diuerb tab (oil of fleabane + theophylline + urea)
  • IDM Expectorant tab (guaifenesin + potassium iodide + pyrilamine maleate + theophylline)
  • IDM tab (potassium iodide + pyrilamine maleate + theophylline)
  • PMS-Oxtriphylline Elixir (alcohol anhydrous + oxtriphylline)
  • Pulmo Septol Sirop (beechwood creosote + cocillana + eucalyptus oil + guaiacol + ipecac + lobelia inflata + myroxylon balsamum + theophylline + white pine)
  • Ratio-theo-bronc (guaifenesin + potassium iodide + pyrilamine maleate + theophylline)
  • Tedral tab (l-ephedrine hydrochloride + phenobarbital + theophylline)
  • Theophylline 0.8mg and 5% dextrose inj (dextrose + theophylline)
  • Theophylline 0.8mg/ml in 5% dextrose inj (dextrose + theophylline)
  • Theophylline 1.6mg and 5% dextrose inj (dextrose + theophylline)
  • Theophylline 4mg and 5% dextrose inj (dextrose + theophylline)
  • Theophylline rougier elixir (alcohol anhydrous + theophylline)

    • Quibron-T Formula chimica

    C7H8N4O2

    Quibron-T RX link

    http://www.rxlist.com/cgi/generic/theosr.htm

    Quibron-T FDA foglio

    Quibron-T FDA

    Quibron-T DMS (foglio di materiale di sicurezza)

    Quibron-T MSDS

    Quibron-T Sintesi di riferimento

    Traube, Ber. 33, (1940)

    Quibron-T Peso molecolare

    180.164 g/mol

    Quibron-T Temperatura di fusione

    272 oC

    Quibron-T H2O Solubilita

    1-5 g / L

    Quibron-T Stato

    Solid

    Quibron-T LogP

    -0.773

    Quibron-T Forme di dosaggio

    Capsule (rilascio prolungato), Elisir, liquidi; Tablet; Tablet (a rilascio prolungato)

    Quibron-T Indicazione

    Per il trattamento dei sintomi e ostruzione delle vie aeree reversibile associata con asma cronica e altre malattie polmonari croniche, come l'enfisema e la bronchite cronica.

    Quibron-T Farmacologia

    Teofillina, un derivato xantina chimicamente simile alla caffeina e la teobromina, è usato per curare l'asma e broncospasmo. La teofillina ha due azioni distinte nelle vie aeree dei pazienti con reversibile (Asmatici) ostruzione; rilassamento della muscolatura liscia (cioè, broncodilatazione) e la soppressione della risposta delle vie aeree a stimoli (cioè non-broncodilatatore effetti profilattici).

    Quibron-T Assorbimento

    La teofillina è rapidamente e completamente assorbito dopo somministrazione orale in soluzione o rilascio immediato forma solida dosaggio orale.

    Quibron-T Tossicita

    Sintomi di sovradosaggio includono convulsioni, aritmie, e gli effetti gastrointestinali.

    Quibron-T Informazioni paziente

    Immediate Release Products

    The patient (or parent/care giver) should be instructed to seek medical advice whenever nausea, vomiting, persistent headache, insomnia or rapid heart beat occurs during treatment with theophylline, even if another cause is suspected. The patient should be instructed to contact their clinician if they develop a new illness, especially if accompanied by a persistent fever, if they experience worsening of a chronic illness, if they start or stop smoking cigarettes or marijuana, or if another clinician and a new medication or discontinues a previously prescribed medication. Patients should be instructed to inform all clinicians involved in their care that they are taking theophylline, especially when a medication is being added or deleted from their treatment. Patients should be instructed to not alter the dose, timing of the dose, or frequency of administration without first consulting their clinician. If a dose is missed, the patient should be instructed to take the next dose at the usually scheduled time and to not attempt to make up for the missed dose.

    Extended-Release Capsules

    This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

    The physician should reinforce the importance of taking only the prescribed dose and the time interval between doses. As with any controlled-release theophylline product, the patient should alert the physician of symptoms occur repeatedly, especially near the end of the dosing interval.

    When prescribing administration by the sprinkle method, details of the proper technique should be explained to patient

    Patients should be informed of the need to take this drug in the fasting state, and that drug administration should be 1 hour before or 2 hours after meals.

    Quibron-T Atto interessato organismi

    Gli esseri umani e altri mammiferi